Related Experiment Video
Updated: Jul 2, 2026
10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
RNA interference: new therapeutics in allergic diseases
Chen-Chen Lee1, Bor-Luen Chiang
1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Current Gene Therapy
|August 12, 2008
Summary
RNA interference (RNAi) therapeutics show promise for treating allergic diseases. Further research into RNAi mechanisms and delivery methods is needed for clinical success.
Area of Science:
- Biotechnology
- Immunology
- Genetics
Background:
- RNA interference (RNAi) mechanisms were established in 1990.
- RNAi therapeutics have advanced from animal studies to human clinical trials for various diseases.
- Allergic diseases represent a significant area with potential for RNAi-based treatments.
Purpose of the Study:
- To review RNAi therapeutics specifically for allergic diseases.
- To discuss RNAi mechanisms, design, challenges, and potential targets in allergy.
- To summarize current in vitro and in vivo studies of RNAi therapy for allergies.
Main Methods:
- Literature review of RNAi mechanisms and applications.
- Analysis of studies investigating RNAi therapy in allergic disease models.
- Synthesis of information on challenges and targets for RNAi in allergy.
Main Results:
- RNAi therapeutics demonstrate significant potential for treating allergic diseases.
- Current research includes in vitro and in vivo studies exploring RNAi efficacy.
- Several potential targets and design strategies for RNAi in allergy have been identified.
Conclusions:
- RNAi-based therapy holds promise for allergic diseases.
- Further elucidation of detailed RNAi mechanisms is necessary.
- Development of more effective delivery methods is crucial for future clinical translation.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
02:06Allergic Reactions
Overview
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...